Deutsche Bank
ADAP

Deutsche Bank’s Adaptimmune Therapeutics ADAP Stock Holding History

Deutsche Bank’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-534
Closed -$3K – 4527
2020
Q4 		$3K Buy
+534
New +$2.9K ﹤0.01% 4363
2020
Q1 		– Sell
-92
Closed – – 4293
2019
Q4 		$0 Sell
92
-770
-89% -$821 ﹤0.01% 4971
2019
Q3 		$1K Sell
862
-19,564
-96% -$45.7K ﹤0.01% 4795
2019
Q2 		$81K Sell
20,426
-277,475
-93% -$1.13M ﹤0.01% 4309
2019
Q1 		$1.28M Buy
297,901
+180,201
+153% +$839K ﹤0.01% 2827
2018
Q4 		$676K Buy
117,700
+108,142
+1,131% +$798K ﹤0.01% 3132
2018
Q3 		$130K Sell
9,558
-122,135
-93% -$1.28M ﹤0.01% 4408
2018
Q2 		$1.56M Sell
131,693
-204,193
-61% -$2.55M ﹤0.01% 3124
2018
Q1 		$3.77M Buy
335,886
+160,940
+92% +$1.41M ﹤0.01% 2439
2017
Q4 		$1.17M Sell
174,946
-116,088
-40% -$897K ﹤0.01% 3091
2017
Q3 		$2.38M Buy
291,034
+38,809
+15% +$242K ﹤0.01% 2417
2017
Q2 		$1.13M Buy
252,225
+138,519
+122% +$724K ﹤0.01% 2945
2017
Q1 		$625K Buy
+113,706
New +$497K ﹤0.01% 2956
2016
Q4 		– Sell
-23,349
Closed -$164K – 4885
2016
Q3 		$164K Buy
+23,349
New +$178K ﹤0.01% 3741
2016
Q1 		– Sell
-500
Closed -$6K – 5123
2015
Q4 		$6K Buy
+500
New +$4.9K ﹤0.01% 5022

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Deutsche Bank's ADAP Position: Q1 2021 in Review

Deutsche Bank sold out of Adaptimmune Therapeutics (ADAP) in Q1 2021, closing a stake of 534 shares — an estimated $3K sold.

Deutsche Bank first reported a position in ADAP in Q4 2015 and held it in 15 quarters. The position peaked at $3.77M in Q1 2018. 84 funds tracked by Wall St. Rank hold ADAP as of Q1 2021.

  • Deutsche Bank reported no remaining Adaptimmune Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Deutsche Bank sold 534 Adaptimmune Therapeutics shares in Q1 2021, an estimated $3K.
  • Deutsche Bank first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 15 quarters.
  • Deutsche Bank's Adaptimmune Therapeutics position peaked at $3.77M in Q1 2018.
  • 84 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2021.

Based on Deutsche Bank's 13F filing for Q1 2021, filed 13 May 2021.